Ultragenyx Pharma (RARE) Misses Q3 EPS by 58c, provides guidance

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.81), $0.58 worse than the analyst estimate of ($1.23). Revenue for the quarter came in at $160 million versus the consensus estimate of $167 million.

GUIDANCE:

Ultragenyx Pharma sees FY 2025 revenue of $640-670 million, versus the consensus of $657.4 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• U.S. presses Meta to agree to A.I. reviews as security concerns rise - NYT
• Alphabet to replace Verizon in the Dow Jones Industrial Average